Movers & Shakers

This is an excerpt from Cabot Top Ten Trader, which features the best trades to make every week.  Designed for experienced investors who want even more great growth stock ideas, this advisory recommends the best 10 stocks each month for short-term investment by aggressive growth investors.

It’s been a very interesting week, so let’s get right to it.

From a top-down perspective, the market remains in good shape. By our measures, the intermediate-term trend turned up in early October, and since then, we can’t say much bad about the action of the major indexes—pullbacks have generally been brief and have been followed by strong upmoves to new recovery highs. And this morning’s pop is also encouraging.

Now, as we’ve written during the past couple of weeks, we’re still seeing most of the action in either beaten-down groups or, more recently, defensive stocks (consumer staples, tobacco, etc.), which isn’t ideal. And some of the growth-oriented indexes (mainly small- and mid-caps) have been lagging a bit, too.

Still, we focus mostly on the overall trend, so we have to conclude the overall market is supportive of the bulls here.

But below the surface, the action has been incredibly wild, with some stocks and sectors imploding while others ramp higher. Of course, some of that is due to earnings season, but the moves are exaggerated even taking that into account.

With all these crosscurrents, it’s easy to get confused, but we’re just sticking with our game plan of taking our cues from the action of leading stocks—if many of them get going (ideally lifting out of multi-month bases following earnings reports), not only are those stocks buyable but it would bode well for the market’s rally. If, however, many falter (we’ve seen quite a few blowups this week), it’s best to go slow and hold some cash.

Overall, we are cautiously optimistic; there’s enough evidence to do some buying in strong stocks. The pieces are in place for a good run in Top Ten (i.e., high relative strength) stocks … but we’re waiting for further confirmation before from those stocks before becoming heavily invested.

Michael Cintolo can be found on Google Plus.

Stock Picks

Loews Corp.

This undervalued stock has strong future earnings growth expectations.


Biogen is the market-share leader in treating multiple sclerosis.


One of Paul Godwin’s favorite stocks in his Cabot Emerging Markets Investor portfolio.

Cabot Wealth Advisory

Does Alibaba (BABA) Stock Measure Up to Amazon (AMZN)?

By Paul Goodwin on September 23, 2016

Alibaba (BABA) is the Amazon (AMZN) of China. But does BABA stock measure up to AMZN stock? Let’s break it down!Read More >

As Stock Market Trends Change, Invest in these New Leaders

By Michael Cintolo on September 22, 2016

History tells us that all stock market trends change, and if you don’t recognize the leaders of that change early, you risk missing out on the next big winners.Read More >

AMZN Stock vs. FB Stock: Which Is the Better Value Buy?

By J. Royden Ward on September 20, 2016

For the past five years, AMZN stock and FB stock have been two of the market's great growth stories. But could you make the case that either stock is still undervalued? Let’s break it down.Read More >